arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

GALECTIN THERAPEUTICS INC

GALT
$3.45 ▲ +0.21 (+6.48%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
79
Health
Good
Bullish
auto_awesome

Analytical Summary

GALECTIN THERAPEUTICS INC shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $226.9M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 2.4%
FCF / Share $-0.06
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-5.05M
↑ +47.6%
FCF / Share Free cash flow per share
$-0.06
↑ +51.7%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
90
Cash Quality
52

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters